3-D Matrix, Ltd.
Q1 2027 Financial Summary (Consolidated) [Japanese GAAP]
For the first quarter of the April 2027 term, consolidated net sales were 3,225 million yen, operating income was 494 million yen, ordinary income was 342 million yen, and net income attributable to owners of the parent was 302 million yen. YoY, net sales increased by 46.9%, operating income turned to a substantial profit (previous quarter: 9 million yen), ordinary income declined due to foreign exchange losses, and net income attributable to owners of the parent decreased YoY. There is no revision to the full-year projections from the previous release.
Key Figures
- Net sales: 3,225 million yen
- Operating income: 494 million yen
- Net income attributable to owners of the parent: 302 million yen
AI要約
Overview of performance
For this first quarter, consolidated net sales were 3,225 million yen, up 46.9% YoY. Sales were strong mainly in the US market, with especially large contributions from the GI/endoscopy area, while the Japanese market declined. Operating income turned to a profit at 494 million yen, but ordinary income was 342 million yen due to foreign exchange losses, and net income attributable to owners of the parent was 302 million yen, down YoY. There is no change to the full-year forecast.
Outlook and impact for investors
Continued expansion in the US market and new-area development in Europe are expected, with a corresponding improvement in profitability along with sales growth. However, foreign exchange effects remain a risk to monitor. The company is promoting wider use of PureStat as a wound healing and hemostatic material, and aims to accumulate preclinical and clinical evidence and obtain approvals in the United States.
3-D Matrix, Ltd.
Company overview · Stock price · Financial data · All IR
